DK0533840T3 - Behandling af kronisk nyresvigt med imidazol-angiotensin-II-receptor-antagonister - Google Patents

Behandling af kronisk nyresvigt med imidazol-angiotensin-II-receptor-antagonister

Info

Publication number: DK0533840T3
Authority: DK; Denmark
Prior art keywords: imidazole; angiotensin; renal failure; chronic renal; treatment
Prior art date: 1990-06-22

Application number

DK91912884.3T

Other languages

Danish (da)

English (en)

Inventor

David John Carini

John Jonas Vytautas Duncia

Pancras Chor-Bun Wong

Original Assignee

Du Pont

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-06-22

Filing date

1991-06-07

Publication date

1996-12-30

1991-06-07 Application filed by Du Pont filed Critical Du Pont

1996-12-30 Application granted granted Critical

1996-12-30 Publication of DK0533840T3 publication Critical patent/DK0533840T3/da

Links

208000020832 chronic kidney disease Diseases 0.000 title abstract 2
208000022831 chronic renal failure syndrome Diseases 0.000 title abstract 2
239000002333 angiotensin II receptor antagonist Substances 0.000 title 1
UUPNFNCKGJOLQE-UHFFFAOYSA-N 2-[4-[[2-butyl-4-chloro-5-(hydroxymethyl)imidazol-1-yl]methyl]phenyl]benzoic acid Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C(O)=O)C=C1 UUPNFNCKGJOLQE-UHFFFAOYSA-N 0.000 abstract 1
102000005862 Angiotensin II Human genes 0.000 abstract 1
101800000733 Angiotensin-2 Proteins 0.000 abstract 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 1
229950006323 angiotensin ii Drugs 0.000 abstract 1
150000002460 imidazoles Chemical class 0.000 abstract 1
PSIFNNKUMBGKDQ-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 PSIFNNKUMBGKDQ-UHFFFAOYSA-N 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK91912884.3T 1990-06-22 1991-06-07 Behandling af kronisk nyresvigt med imidazol-angiotensin-II-receptor-antagonister DK0533840T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US54235190A	1990-06-22	1990-06-22

Publications (1)

Publication Number	Publication Date
DK0533840T3 true DK0533840T3 (da)	1996-12-30

Family

ID=24163446

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK91912884.3T DK0533840T3 (da)	1990-06-22	1991-06-07	Behandling af kronisk nyresvigt med imidazol-angiotensin-II-receptor-antagonister

Country Status (8)

Country	Link
EP (1)	EP0533840B1 (fr)
JP (2)	JPH05509086A (fr)
AT (1)	ATE146076T1 (fr)
CA (1)	CA2085584C (fr)
DE (1)	DE69123582T2 (fr)
DK (1)	DK0533840T3 (fr)
GR (1)	GR3022035T3 (fr)
WO (1)	WO1992000067A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2058198A1 (fr) *	1991-01-04	1992-07-05	Adalbert Wagner	Procede de preparation et utilisation de derives d'azole
JP3810020B2 (ja) *	1993-04-22	2006-08-16	武田薬品工業株式会社	腎疾患の予防または治療剤
FR2719598B1 (fr) *	1994-05-03	1996-07-26	Rhone Poulenc Chimie	Composition élastomère silicone et ses applications, notamment pour l'enduction de sac gonflable, destiné à la protection d'un occupant de véhicule.
AU677702B2 (en) *	1994-10-13	1997-05-01	Takeda Pharmaceutical Company Limited	A prophylactic or therapeutic drug for renal diseases
US6498142B1 (en) *	1996-05-06	2002-12-24	Curis, Inc.	Morphogen treatment for chronic renal failure
DE69826854T2 (de)	1997-05-05	2006-02-02	Curis, Inc., Cambridge	Therapien zur behandlung von akutem nierenversagen
SE9903028D0 (sv)	1999-08-27	1999-08-27	Astra Ab	New use
CA2735478C (fr)	2001-01-26	2014-07-08	Chugai Seiyaku Kabushiki Kaisha	Inhibiteurs de malonyl-coa decarboxylase utiles comme modulateurs metaboliques
EP1377290B1 (fr)	2001-01-26	2006-10-04	Chugai Seiyaku Kabushiki Kaisha	Inhibiteurs de malonyl-coa decarboxylase utiles en tant que modulateurs metaboliques
DE60219595T2 (de)	2001-01-26	2008-01-10	Chugai Seiyaku K.K.	Verfahren zur behandlung von erkrankungen mit malonyl coa-decarboxylase-inhibitoren
PL204456B1 (pl)	2001-02-20	2010-01-29	Chugai Pharmaceutical Co Ltd	Związki azolowe, ich zastosowanie i środek farmaceutyczny
US7709510B2 (en)	2001-02-20	2010-05-04	Chugai Seiyaku Kabushiki Kaisha	Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
ATE536872T1 (de)	2003-08-01	2011-12-15	Chugai Pharmaceutical Co Ltd	Azol-verbindungen auf cyanoguanidin-basis als malonyl-coa decarboxylase-hemmer
EP1653957B1 (fr)	2003-08-01	2008-07-09	Chugai Seiyaku Kabushiki Kaisha	Composes de piperidine utiles en tant qu'inhibiteurs de malonyl-coa decarboxylase
US7696365B2 (en)	2003-08-01	2010-04-13	Chugai Seiyaku Kabushiki Kaisha	Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors
ES2295930T3 (es)	2003-08-01	2008-04-16	Chugai Seiyaku Kabushiki Kaisha	Compuestos de cianoamida utiles como inhibidores de malonil-coa descarboxilasa.
US8257797B2 (en)	2003-11-03	2012-09-04	Bluestar Silicones France	Silicone composition and process that is useful for improving the tear strength and the combing strength of an inflatable bag for protecting an occupant of a vehicle
ES2393885T7 (es)	2007-06-04	2014-01-30	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP2011518884A (ja) *	2008-04-29	2011-06-30	セラヴァンス，インコーポレーテッド	二重活性抗高血圧剤
CA2930674A1 (fr)	2008-06-04	2009-12-10	Synergy Pharmaceuticals Inc.	Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
JP2011528375A (ja)	2008-07-16	2011-11-17	シナジーファーマシューティカルズインコーポレイテッド	胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
JPWO2011077712A1 (ja) *	2009-12-22	2013-05-02	興和株式会社	新規な１−（ビフェニル−４−イル−メチル）−１ｈ−イミダゾール誘導体及びこれを含有する医薬
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
EP2968439A2 (fr)	2013-03-15	2016-01-20	Synergy Pharmaceuticals Inc.	Compositions utiles pour le traitement de troubles gastro-intestinaux
WO2014151206A1 (fr)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Agonistes de la guanylate cyclase et leurs utilisations
US10011637B2 (en)	2013-06-05	2018-07-03	Synergy Pharmaceuticals, Inc.	Ultra-pure agonists of guanylate cyclase C, method of making and using same
CN109715615A (zh)	2016-06-29	2019-05-03	蒙特利尔大学	联芳甲基杂环

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5015651A (en) *	1988-01-07	1991-05-14	E. I. Du Pont De Nemours And Company	Treatment of hypertension with 1,2,4-angiotensin II antagonists
EP0955294B1 (fr) *	1989-06-14	2003-09-24	Smithkline Beecham Corporation	Acides imidazoalcénoiques
EP0479903B1 (fr) *	1989-06-30	1996-02-21	E.I. Du Pont De Nemours And Company	Imidazoles substitues utiles comme inhibiteurs de l'angiotensin ii
CA2032289A1 (fr) *	1989-12-29	1991-06-30	Joseph A. Finkelstein	5-(alkyl)carboxamideimidazoles substitues

1991
- 1991-06-07 CA CA002085584A patent/CA2085584C/fr not_active Expired - Lifetime
- 1991-06-07 DK DK91912884.3T patent/DK0533840T3/da active
- 1991-06-07 DE DE69123582T patent/DE69123582T2/de not_active Expired - Lifetime
- 1991-06-07 AT AT91912884T patent/ATE146076T1/de not_active IP Right Cessation
- 1991-06-07 EP EP91912884A patent/EP0533840B1/fr not_active Expired - Lifetime
- 1991-06-07 JP JP3512070A patent/JPH05509086A/ja active Pending
- 1991-06-07 WO PCT/US1991/003906 patent/WO1992000067A2/fr active IP Right Grant
1996
- 1996-12-13 GR GR960403462T patent/GR3022035T3/el unknown
1998
- 1998-11-12 JP JP10321761A patent/JPH11228410A/ja active Pending

Also Published As

Publication number	Publication date
JPH05509086A (ja)	1993-12-16
DE69123582T2 (de)	1997-05-15
EP0533840B1 (fr)	1996-12-11
EP0533840A1 (fr)	1993-03-31
WO1992000067A3 (fr)	1993-05-27
CA2085584C (fr)	2003-02-11
JPH11228410A (ja)	1999-08-24
GR3022035T3 (en)	1997-03-31
CA2085584A1 (fr)	1991-12-23
DE69123582D1 (de)	1997-01-23
ATE146076T1 (de)	1996-12-15
WO1992000067A2 (fr)	1992-01-09

Publication	Publication Date	Title
DK0533840T3 (da)	1996-12-30	Behandling af kronisk nyresvigt med imidazol-angiotensin-II-receptor-antagonister
EP0803252A3 (fr)	1997-11-26	Traitement de désordres du système nerveux central avec des antagonistes récepteurs d'imidazole angiotensine II
NO1995004I1 (no)	1995-05-26	Losartan/ 2-butyl-4-klor-1-((2'-(1H-tetrazol-5-yl)-bifenyl-4-yl)-metyl)-5-(hydroksylmetyl)-imidazol
DE69007740D1 (de)	1994-05-05	Substituierte 5-[(Tetrazolyl)alkenyl]-Imidazole.
DE69413523D1 (de)	1998-10-29	Benzimidazole derivate
MX9204737A (es)	1994-02-28	Acidos imidazolil-alquenoicos
DK0403159T3 (da)	2000-08-14	Imidazolylalkensyrer
DE69724246D1 (de)	2003-09-25	Neue substituierte imidazolverbindungen
DE69025473D1 (de)	1996-03-28	Substituierte imidazole und ihre verwendung als hemmmstoff fur angiotensin ii
ES2117014T3 (es)	1998-08-01	Quinazolinonas substituidas en las posiciones 2,3,6 bloqueadoras del receptor de la angiotensina ii.
BR9708517A (pt)	1999-08-03	Composição farmacêutica processo para prevenir ou tratar doenças mediadas por angiotensina ii em um mamífero e uso de um composto
ATE302205T1 (de)	2005-09-15	Thieno- und furopyrimidin derivate als a2a- rezeptor antagonisten
DE68907921D1 (de)	1993-09-09	Substituierte pyrrol-, pyrazol- und triazol-angiotensin ii-antagonisten.
NZ330889A (en)	2000-03-27	Cycloalkyl substituted imidazoles and their use in treating CSB/RK/p38 kinase mediated diseases
NO972324D0 (no)	1997-05-21	Orale blandinger inneholdende Ondansetron
DE60126652D1 (de)	2007-03-29	Indolderivate
RO118870B1 (ro)	2003-12-30	Monometansulfonat de acid (e)-alfa-[2-n-butil-1-[(4-carboxifenil)metil]-1h-imidazol-5-il]metilen-2-tiofenpropionic, procedee de preparare şi compoziţii farmaceutice
BR9104918A (pt)	1992-06-23	Utilizacao de compostos bloqueadores do receptor de angiotensina-ii,processo para o tratamento da hipertrofia e/ou hiperplasia cardial e vascular,processo para a obtencao de um preparo farmaceutico e composicao farmaceutica
MY106159A (en)	1995-03-31	Substituted n-(imidazolyl)alkyl alanine derivatives.
TR199701536T1 (xx)	1998-02-21	Benzimidazollerin, l�seminin tedavisi i�in bir ila� �retilmesinde kullan�m�.
DK1632248T3 (da)	2011-01-24	Anti-interleukin-9-antistof eller anti-interleukin-9-receptor-antistof til behandling af bronkial overfølsomhed
PT1019048E (pt)	2004-05-31	Uso de um antagonista do receptor da angiotensina ii para a preparacao de farmacos para aumentar a taxa de sobrevivencia de pacientes sujeitos a transplante renal
MY111445A (en)	2000-05-31	Ondansetron for rectal administration
DK1287832T3 (da)	2006-05-01	Anvendelse af antagonist af leukæmiinhiberende faktor